Psychopharmacology in dermatology: Treatment of primary psychiatric conditions in dermatology.
primary psychiatric disorders
psychodermatology
psychotropic drugs
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
24
04
2020
revised:
06
05
2020
accepted:
07
05
2020
pubmed:
13
5
2020
medline:
15
5
2021
entrez:
13
5
2020
Statut:
ppublish
Résumé
The role of psychotropic drugs in psychodermatology is still debatable, due to the quality of the evidence that supports it. There are several case reports and open trials with variable results. There is an additional difficulty in finding therapists trained in effective psychotherapy techniques, justify the need for more research on the available pharmacological options. The present review emphasizes pharmacological treatment in psychodermatology, specifically in cases of primary psychiatric disorders that are expressed with self-inflicted cutaneous signs and symptoms, in which drugs can play a central role in ameliorating symptoms or be useful in combination with psychotherapeutic approach of these disorders.
Substances chimiques
Psychotropic Drugs
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13557Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Jafferany M, Franca K. Psychodermatology: basic concepts. Acta Derm Venereol. 2016 Aug 23;96(217):35-37. https://doi.org/10.2340/00015555-2378.
Yadav S, Narang T, Kumaran MS. Psychodermatology: A comprehensive review. Indian J Dermatol Venereol Leprol. 2013;79(2):176-192. https://doi.org/10.4103/0378-6323.107632.
Chamberlain SR, Menzies LA, Fineberg NA, et al. Grey matter abnormalities in trichotillomania: morphometric magnetic resonance imaging study. Br J Psychiatry. 2008;193(3):216-221. https://doi.org/10.1192/bjp.bp.107.048314.
Seale L, Gaulding J, Porto D, Prabhakar D, Kerr H. Implementation of a psychodermatology clinic at a major health system in Detroit. Int J Women's Dermatol. 2018;4(4):227-229. https://doi.org/10.1016/j.ijwd.2018.05.002.
Harrison P, Baldwin D, Barnes T, et al. No psychiatry without psychopharmacology. Br J Psychiatry. 2011;199(4):263-265. https://doi.org/10.1192/bjp.bp.111.094334.
Jafferany M, Patel A. Understanding psychocutaneous disease: psychosocial and psychoneuroimmunological perspectives. Int J Dermatol. 2019;59:8-15. https://doi.org/10.1111/ijd.14629.
Koo J, Lebwohl A. Psychodermatology: the mind and skin connection. Am Fam Physician. 2001;64(11):1873-1878.
Rodríguez-Cerdeira C, Pera-Grasa JT, Molares-Vila A, Isa-Isa R, Arenas-Guzmán R. Psychodermatology: past, present and future. Open Dermatol J. 2011;5(1):21-27.
Anthis Lista. Skin disease and relationships. Walker Carl, Papadopoulos Linda, Psychodermatology: the Psychological Impact of Skin Disorders. New York: Cambridge University Press; 2005;72-88.
Evers A, Duller P, van de Kerkhof P, et al. The impact of chronic skin disease on daily life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol. 2008;158(01):101-108. https://doi.org/10.1111/j.1365-2133.2007.08296.x.
Jafferany M, Osuagwu FC. Evaluation of body parts that preoccupy adolescents with body dysmorphic disorder. Prim Care Companion CNS disord. 2017;19(5):17m02154.
Crerand CE, Menard W, Phillips KA. Surgical and minimally invasive cosmetic procedures among persons with body dysmorphic disorder. Ann Plast Surg. 2010;65(1):11-16. https://doi.org/10.1097/SAP.0b013e3181bba08f.
Sarwer DB, Crerand CE, Magee L. Body dysmorphic disorder in patients who seek appearance-enhancing medical treatments. Oral Maxillofac Surg Clin North Am. 2010;22(4):445-453. https://doi.org/10.1016/j.coms.2010.07.002.
Ipser JC, Sander C, Stein DJ. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst Rev. 2009;1:CD005332. https://doi.org/10.1002/14651858.CD005332.pub2.
Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59(4):381-388.
Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image. 2008;5(1):13-27. https://doi.org/10.1016/j.bodyim.2007.12.003.
Phillips KA. Pharmacotherapy for body dysmorphic disorder. Psychiatr Ann. 2010;40(7):325-332. https://doi.org/10.3928/00485713-20100701-05.
Saxena S, Winograd A, Dunkin JJ. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder. J Clin Psychiatry. 2001;62:67-72.
Hong K, Nezgovorova V, Uzunova G, Schlussel D, Hollander E. Pharmacological treatment of body dysmorphic disorder. Curr Neuropharmacol. 2019;17(8):697-702. https://doi.org/10.2174/1570159X16666180426153940.
Torales J, González L, Ruiz Díaz C, Navarro R. Delirio de infestación [Delusional infestation]. In: Torales J, Malatesta E, eds. Psicodermatología: una actualización diagnóstica y terapéutica de las entidades clínicas más frecuentes [Psychodermatology: a diagnostic and therapeutic update of the most frequent clinical entities]. 1st ed. Asunción: EFACIM; 2019:62-79.
Escalas J, Guerra A, Rodríguez-Cerdeira M. Tratamiento con psicofármacos de los trastornos psicodermatológicos [Psychopharmaceutical treatment of psychodermatological disorders]. Actas Dermosifiliogr. 2010;101(6):485-494. https://doi.org/10.1016/j.ad.2009.12.027.
Jafferany M, Vander Stoep A, Dumitrescu A, Hornung RL. The knowledge, awareness, and practice patterns of dermatologists toward psychocutaneous disorders: results of a survey study. Int J Dermatol. 2010;49(7):784-789. https://doi.org/10.1111/j.1365-4632.2009.04372.x.
Odlaug BL, Hampshire A, Chamberlain SR, Grant JE. Abnormal brain activation in excoriation (skin-picking) disorder: evidence from an executive planning fMRI study. Br J Psychiatry. 2016;208(2):168-174. https://doi.org/10.1192/bjp.bp.114.155192.
Lochner C, Roos A, Stein DJ. Excoriation (skin-picking) disorder: a systematic review of treatment options. Neuropsychiatr Dis Treat. 2017;13:1867-1872. https://doi.org/10.2147/NDT.S121138.
Torales J, Villalba J, Ruiz Díaz N, González I. Trastorno de excoriación [Excoriation disorder]. In: Torales J, Malatesta E, eds. Psicodermatología: una actualización diagnóstica y terapéutica de las entidades clínicas más frecuentes [Psychodermatology: a diagnostic and therapeutic update of the most frequent clinical entities]. 1st ed. Asunción: EFACIM; 2019:80-106.
Adil M, Amin S, Mohtashim M. N-acetylcysteine in dermatology. Indian J Dermatol Venereol Leprol. 2018;84(6):652. https://doi.org/10.4103/ijdvl.ijdvl_33_18.
Bloch MR, Elliott M, Thompson H, Koran LM. Fluoxetine in pathologic skin-picking: open-label and double-blind results. Psychosomatics. 2001;42:314-319.
Grant J, Chamberlain S, Redden S, Leppink E, Odlaug B, Kim S. N-acetylcysteine in the treatment of excoriation. JAMA Psychiat. 2016;73(5):490-496. https://doi.org/10.1001/jamapsychiatry.2016.0060.
Jafferany M, Osuagwu F. Use of Topiramate in skin-picking disorder. Prim Care Compan CNS Disord. 2017;19(1):16m01961. https://doi.org/10.4088/PCC.16m01961.
Kiliç F, Süleyman K. Repetitive behaviors treated with N-acetylcysteine: case series. Clin Neuropharmacol. 2019;42(4):1. https://doi.org/10.1097/WNF.0000000000000352.
Kim D, Ryba NL, Kalabalik J, Westrich L. Critical review of the use of second-generation antipsychotics in obsessive-compulsive and related disorders. Drugs R&D. 2018;18(3):167-189. https://doi.org/10.1007/s40268-018-0246-8.
Nwankwo CO, Jafferany M. N-acetylcysteine in psychodermatological disorders. Dermatol Ther. 2019 Sep;32(5):e13073. https://doi.org/10.1111/dth.13073.
Rodrigues Barata AR, Tosti A, Rodriguez Pichardo A, Camacho MF. N-acetylcysteine in the treatment of trichotillomania. Int J Trichol. 2012;4(3):176-178. https://doi.org/10.4103/0974-7753.100090.
Rothbart R, Stein DJ. Pharmacotherapy of trichotillomania (hair pulling disorder): an updated systematic review. Expert Opin Pharmacother. 2014;15(18):2709-2719. https://doi.org/10.1517/14656566.2014.972936.
Suh K, Keystone J. Treatment of delusional infestation. In: Marder S, Stratman E, eds. Up-to-Date. Waltham, MA: UpToDate; 2018.
Torales J. Delusional infestations. In: Bhugra D, Malhi G, eds. Troublesome Disguises: Managing Challenging Disorders in Psychiatry. 2nd ed. London: Wiley Blackwell; 2015:252-261. https://doi.org/10.1002/9781118799574.
Mercan S, Altunay I, Taskintuna N, Ogutcen O, Kayaoğlu S. Atypical antipsychotic drugs in the treatment of delusional Parasitosis. Int J Psych Med. 2007;37(1):29-37. https://doi.org/10.2190/M8M5-H1G2-1257-2017.
Freudenmann R, Lepping P, Huber M, et al. Delusional infestation and the specimen sign: a European multicentre study in 148 consecutive cases. Br J Dermatol. 2012;167(2):247-251. https://doi.org/10.1111/j.1365-2133.2012.10995.x.
Lepping P, Russell I, Freudenmann R. Antipsychotic treatment of primary delusional parasitosis. Br J Psychiatry. 2007;191(03):198-205. https://doi.org/10.1192/bjp.bp.106.029660.
Assalman I, Bewley AP, Alhajjar R, Ahmed A, Taylor R. Treatments for primary delusional infestation. Cochrane Database Syst Rev. 2014;10:CD011326. https://doi.org/10.1002/14651858.CD011326.
Bennassar A, Guilabert A, Alsina M, Pintor L, Mascaro JM Jr. Treatment of delusional parasitosis with aripiprazole. Arch Dermatol. 2009;145(4):500-501. https://doi.org/10.4103/0972-6748.98422.
Katsoulis K, Rutledge KJ, Jafferany M. Delusional infestations: A prototype of psychodermatological disorder. Int J Dermatol. 2020;59(5):551-560.
Freudenmann R, Lepping P. Delusional infestation. Clin Microbiol Rev. 2009;22(4):690-732. https://doi.org/10.1128/CMR.00018-09.
Rodríguez Pichardo A, García BB. Dermatitis artefacta: revisión [dermatitis artefacta: a review]. Actas Dermosifiliogr. 2013;104(10):854-866. https://doi.org/10.1016/j.ad.2012.10.004.
Mohandas P, Bewley A, Taylor R. Dermatitis artefacta and artefactual skin disease: the need for a psychodermatology multidisciplinary team to treat a difficult condition. Br J Dermatol. 2013;169(3):600-606. https://doi.org/10.1111/bjd.12416.
Kępska A, Majtyka M, Kowman M, Kłoszewska I, Kwiecińska E, Zalewska-Janowska A. Dermatitis artefacta as a symptom of schizophrenia? Adv Dermatol Allergol. 2014;31(4):277-279. https://doi.org/10.5114/pdia.2014.40921.
Jafferany M, Stamu-O'Brien C, Mkhoyan R, Patel A. Psychotropic drugs in dermatology: A dermatologist's approach and choice of medications. Dermatol Ther. 2020;e13385. https://doi.org/10.1111/dth.13385. [Epub ahead of print].
Rodríguez M, García Contreras SJ. Dermatitis artefacta. Rev Cent Dermatol Pascua. 2010;19(2):59-61.